SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemiae

被引:44
作者
Singh, Onkar [1 ]
Chan, Jason Yongsheng [1 ]
Lin, Keegan [1 ]
Heng, Charles Chuah Thuan [2 ]
Chowbay, Balram [1 ]
机构
[1] Natl Canc Ctr Singapore, Lab Clin Pharmacol, Div Med Sci, Humphrey Oei Inst Canc Res, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Haematol, Singapore 0316, Singapore
来源
PLOS ONE | 2012年 / 7卷 / 12期
关键词
SINGLE-NUCLEOTIDE POLYMORPHISMS; CHRONIC MYELOGENOUS LEUKEMIA; STANDARD-DOSE IMATINIB; GENETIC POLYMORPHISMS; MOLECULAR RESPONSES; PLASMA-LEVELS; CML PATIENTS; TROUGH CONCENTRATION; CANCER-PATIENTS; ASSOCIATION;
D O I
10.1371/journal.pone.0051771
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: This study aimed to explore the influence of SLC22A1, PXR, ABCG2, ABCB1 and CYP3A5*3 genetic polymorphisms on imatinib mesylate (IM) pharmacokinetics in Asian patients with chronic myeloid leukemia (CML). Patients and Methods: Healthy subjects belonging to three Asian populations (Chinese, Malay, Indian; n = 70 each) and CML patients (n = 38) were enrolled in a prospective pharmacogenetics study. Imatinib trough (C-0h) and clearance (CL) were determined in the patients at steady state. Haplowalk method was applied to infer the haplotypes and generalized linear model (GLM) to estimate haplotypic effects on IM pharmacokinetics. Association of haplotype copy numbers with IM pharmacokinetics was defined by Mann-Whitney U test. Results: Global haplotype score statistics revealed a SLC22A1 sub-haplotypic region encompassing three polymorphisms (rs3798168, rs628031 and IVS7+850C>T), to be significantly associated with IM clearance (p = 0.013). Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (*10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017]. Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C-0h than patients carrying 0 or 1 copy [CL(*10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C-0h (*10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively]. Further subgroup analysis revealed SLC22A1 and ABCB1 haplotypic combinations to be significantly associated with clearance and C-0h (p = 0.002 and 0.009, respectively). Conclusion: This exploratory study suggests that SLC22A1-ABCB1 haplotypes may influence IM pharmacokinetics in Asian CML patients. Citation: Singh O, Chan JY, Lin K, Heng CCT, Chowbay B (2012) SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia. PLoS ONE 7(12): e51771. doi:10.1371/journal.pone.0051771
引用
收藏
页数:11
相关论文
共 50 条
[1]   Relationship of serum imatinib trough level and response in CML patients: Long term follow-up [J].
Awidi, Abdalla ;
Ayed, Ayed O. ;
Bsoul, Nazzal ;
Magablah, Ahmad ;
Mefleh, Razan ;
Dweiri, Mohammad ;
Ramahi, Mohammad ;
Arafat, Eyad ;
Bishtawi, Mohammad ;
Marie, Lena .
LEUKEMIA RESEARCH, 2010, 34 (12) :1573-1575
[2]   CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations [J].
Balram, C ;
Zhou, QY ;
Cheung, YB ;
Lee, EJD .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) :123-126
[3]   hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia [J].
Bazeos, A. ;
Marin, D. ;
Reid, A. G. ;
Gerrard, G. ;
Milojkovic, D. ;
May, P. C. ;
de Lavallade, H. ;
Garland, P. ;
Rezvani, K. ;
Apperley, J. F. ;
Goldman, J. M. ;
Foroni, L. ;
Khorashad, J. S. .
LEUKEMIA, 2010, 24 (06) :1243-1245
[4]   Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function [J].
Chen, Ligong ;
Takizawa, Miho ;
Chen, Eugene ;
Schlessinger, Avner ;
Segenthelar, Julie ;
Choi, Ji Ha ;
Sali, Andej ;
Kubo, Michiaki ;
Nakamura, Shinko ;
Iwamoto, Yasuhiko ;
Iwasaki, Naoko ;
Giacomini, Kathleen M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01) :42-50
[5]   Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients [J].
Chowbay, B ;
Cumaraswamy, S ;
Cheung, YB ;
Zhou, QY ;
Lee, EJD .
PHARMACOGENETICS, 2003, 13 (02) :89-95
[6]   Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [J].
Cortes, J. E. ;
Egorin, M. J. ;
Guilhot, F. ;
Molimard, M. ;
Mahon, F-X .
LEUKEMIA, 2009, 23 (09) :1537-1544
[7]   hOCT 1 and resistance to imatinib [J].
Crossman, LC ;
Druker, BJ ;
Deininger, MWN .
BLOOD, 2005, 106 (03) :1133-1134
[8]   Efficiency and power in genetic association studies [J].
de Bakker, PIW ;
Yelensky, R ;
Pe'er, I ;
Gabriel, SB ;
Daly, MJ ;
Altshuler, D .
NATURE GENETICS, 2005, 37 (11) :1217-1223
[9]   Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia [J].
Dulucq, Stephanie ;
Bouchet, Stephane ;
Turcq, Beatrice ;
Lippert, Eric ;
Etienne, Gabriel ;
Reiffers, Josy ;
Molimard, Mathieu ;
Krajinovic, Maja ;
Mahon, Francois-Xavier .
BLOOD, 2008, 112 (05) :2024-2027
[10]   Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting [J].
Faber, Edgar ;
Friedecky, David ;
Micova, Katerina ;
Rozmanova, Sarka ;
Divoka, Martina ;
Jarosova, Marie ;
Indrak, Karel ;
Adam, Tomas .
ANNALS OF HEMATOLOGY, 2012, 91 (06) :923-929